Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

663 - STING, an immune biomarker for colorectal cancer


24 Nov 2018


Poster display - Cocktail


Translational Research

Tumour Site

Colon and Rectal Cancer


Hongjae Chon


Annals of Oncology (2018) 29 (suppl_9): ix28-ix45. 10.1093/annonc/mdy431


H. Chon, D.J. Kim, C. Kim

Author affiliations

  • Medical Oncology, bundang CHA hospital, 13496 - Seongnam/KR


Abstract 663


STING is an innate immune sensor for cytosolic DNA. The activation of STING signaling is indispensable in Type I interferon response and the evocation of anti-cancer immune response by CD8+ T cells. The aim of this study is to characterize intratumoral STING expression pattern and its clinical implication in colorectal cancer (CRC).


We analyzed STING and CD8 expression in 225 CRC patients who underwent surgical resection. Clinicopathological variables and survival outcomes were analyzed according to STING expression level.


Distinct STING expression was observed in tumor specimens of CRCs. Patients with higher STING expression seemed to have early stage cancer (P = 0.001) with increased intratumoral CD8+ T cell infiltration (P < 0.001), and less frequent lymphovascular invasion (P = 0.02). Compared to CRC patients with lower STING expression, those with higher STING expression had longer overall survival (P < 0.001) and recurrence-free survival (P < 0.001). The Cox proportional hazard model adjusted for age, stage, and CD8+ T cells, revealed that higher STING expression is an independent prognostic factor for a better overall survival (P = 0.012, hazard ratio 0.573, 95% CI 0.370 – 0.886).


We have confirmed the distinct STING expression in CRC and demonstrated its independent prognostic value for the survival outcome, thereby suggesting the intratumoral STING expression as a potential immune biomarker for CRC.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Hongjae Chon.


This work was supported by the National Research Foundation of Korea (NRF) grant funded by the the Ministry of Science, ICT & Future Planning (grant NRF-2016R1D1A1B03934012 to H.C.).


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.